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ABSTRACT
CONTEXT AND OBJECTIVE: The concept that the presence of atypical squamous cells cannot exclude 
high-grade squamous intraepithelial lesions (ASC-H) was introduced in the 2001 Bethesda System of cer-
vical cytology classification. This nomenclature defines cervical cancer precursor lesions. The objective of 
this study was to investigate the colpocytological-histological results from a three-year follow-up con-
ducted on a cohort of women with reports of ASC-H who were attended during 2005-2006 at clinics of 
the Southern Metropolitan Healthcare Service of Santiago, Chile.
DESIGN AND SETTING: Prospective cohort study at primary healthcare clinics in Santiago, Chile.
METHODS: Colpocytological-histological follow-up was conducted over a three-year period on 92 wom-
en with cytological reports of ASC-H who were attended at primary healthcare clinics during 2005-2006. 
RESULTS: At the end of the follow-up period, high-grade lesions were evaluated and the following out-
comes were observed: seven women presented invasive cancer (7.6%), 49 presented high-grade lesions 
(53.3%), 26 presented low-grade lesions (28.2%) and 10 presented normal results (10.9%). The “Conditional 
Probabilities Tree Diagram” was used to show the results from tests and the times of lesion detection. It 
demonstrated that, after a first report of ASC-H, clinical management needed to be interventionist. 
CONCLUSION: The follow-up on our cohort of women showed that the majority of uncertain ASC-H diag-
noses (82.6%) had abnormal colposcopic results and that during the follow-up using ASC-H smears, two 
out of every three women developed high-grade lesions. 
RESUMO
CONTEXTO E OBJETIVO: O conceito de que à presença de células escamosas atípicas não se pode excluir 
lesão intraepitelial de alto grau (ASC-H) foi introduzido pelo Sistema de Bethesda 2001, na classificação de 
citologia cervical. Esta nomenclatura define lesões precursoras do câncer cervical. O objetivo deste estudo 
foi investigar os resultados colpo-cito-histológicos de três anos de acompanhamento realizado em uma 
coorte de mulheres com relatórios de ASC-H que receberam atendimento no período 2005-2006 em 
clínicas do Serviço Metropolitano de Saúde Sul de Santiago, Chile.
TIPO DE ESTUDO E LOCAL: Estudo de coorte prospectivo em unidades básicas de saúde de Santiago, Chile.
MÉTODOS: Foi conduzido um acompanhamento colpo-cito-histológico por um período de três anos em 
92 mulheres com laudos citológicos de ASC-H, que receberam atendimento nas unidades básicas de 
saúde de 2005-2006.
RESULTADOS: No final do período de acompanhamento, as lesões de alto grau foram avaliadas e os re-
sultados foram observados: sete mulheres apresentaram câncer invasivo (7,6%), 49 apresentaram lesões 
de alto grau (53,3%), 26 apresentaram lesões de baixo grau (28,2%) e 10 apresentaram resultados normais 
(10,9%). O “Diagrama de Árvore Condicional de Probabilidades” foi utilizado para mostrar os resultados dos 
testes e o período de detecção das lesões, demonstrando que, depois de um primeiro relatório de ASC-H, 
o manejo clínico deve ser intervencionista.
CONCLUSÃO: O acompanhamento de nossa coorte de mulheres mostra que a maioria dos diagnósticos 
incertos de ASC-H (82,6%) tiveram resultado colposcópico anormal e, durante o acompanhamento de 
esses esfregaços ASC-H, duas de cada três mulheres desenvolvem lesões de alto grau.
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INTRODUCTION 
The concept that the presence of atypical squamous cells can-
not exclude high-grade squamous intraepithelial lesion (ASC-H) 
was introduced by the 2001 Bethesda System of cervical cytology 
classification. This system addresses the need to define a cytolog-
ical category between atypical squamous cells of undetermined 
significance (ASCUS) and high-grade squamous intraepithe-
lial lesion (HSIL).1 The definition of this nomenclature resulted 
from the ASCUS/LSIL Triage Study (ALTS) carried out between 
1996 and 2000, in which interpretations of ASCUS were subcat-
egorized as “equivocal LSIL” (ASCUS-L) and “equivocal HSIL” 
(ASCUS-H). Through a consensus among expert pathologists, it 
was concluded that ASCUS-H represented a cytological category 
that differed from ASCUS-L and HSIL.2 ASCUS-H has been seen 
to present a risk association of 27.2% with cervical cancer pre-
cursor lesions, which is higher than the risk association for the 
ASCUS-L category of 11.4%, but lower than the risk association 
for HSIL of 44.8%.2,3
Subsequent studies, such as a study by Sherman et al., 
detected high-grade lesions (HSIL) in 41% of the women with 
initial ASC-H smears.4 Supporting previous findings, Patton 
obtained a high positive predictive value for lesions of cervical 
intraepithelial neoplasia (CIN II/III), derived from the ASC-H 
diagnosis category in a general population of women.5
Bonvicino et al. used computed data from two medical cen-
ters in San Antonio, Texas, United States, in which 260 women 
diagnosed with ASC-H underwent cytological-histological 
follow-up, and found that 25.4% had a high-grade lesion at the 
end of the follow-up period.6 Using the same methodology in 
Brazil, Cytryn et al. found high prevalence of high-grade lesions 
among a total of 57 ASC-H cases.7 Thus, the abovementioned 
follow-up studies demonstrated that there are connections 
between ASC-H smears and high-grade lesions.4,6,7
In Chile, the 2001 Bethesda System was adopted in 2005 
via Ordinance Number B232 1771 issued by the Department of 
Non-Communicable Diseases, within the Division of Disease 
Prevention and Control. This ordinance standardized the use of 
the nomenclature that had started to be used in previous years.8 
In 2006, the National Program for Research and Control of 
Cervical Cancer collected 779,068 Pap smears nationwide, from 
which 14,608 (1.9%) were found to be atypical using the new 
nomenclature.9
Although other studies such as Gaete et al.10 and Yazigi et al.11 
were conducted in Chile, they were limited because they did not 
discriminate the type of atypia given that they were conducted 
using cytological reports that were produced before the 2001 
Bethesda System was incorporated in Chile. The scarce scientific 
evidence regarding the ASC-H category among the female popu-
lation of Chile motivated the present study.
OBJECTIVE
The objective of this study was to investigate the cytological-
histological results from a three-year follow-up conducted on 
a cohort of women with reports of ASC-H who were attended 
during 2005-2006 at clinics within the Southern Metropolitan 
Healthcare Service in Santiago, Chile.  
METHODS
The present research comprises a prospective cohort study on 
women who were followed up over a three-year period. During 
2005-2006, 88,438 cervical cytological smears were collected by 
midwives using Ayre spatulas and cytobrushes in primary health-
care clinics, in the southern area of Santiago, Chile. 
These smear screenings were fixed and sent to Barros Luco 
Hospital Laboratory (central hospital). In this laboratory, the 
cytological smears were stained by means of the conventional Pap 
smear technique and were classified using the national nomen-
clature system, which is equivalent to the 2001 Bethesda system.8 
These tests were processed by a team of cytotechnologists with 
an average of 20 years of experience. Subsequently, these records 
were registered in the “Cytological Expert Diagnosis Archive 
System” at the Chilean Ministry of Health. This provided the 
cytological-histological database that we searched to obtain data 
for the present research study.9
The ASC-H cases were selected (n = 106) and the following 
selection criteria were applied: the women needed to be with-
out uterine pathological conditions, without prior cervical pro-
cedures and with normal Pap smear results for the last three 
years. These criteria resulted in a cohort of 92 women who were 
followed up colpocytologically-histologically for a three-year 
period or until their cases were resolved.
The clinical management of these women included gyne-
cological examinations, cytological tests (Pap smears), col-
poscopic examinations and biopsies. HPV testing was not 
performed due to cost constraints. All of the follow-up tests 
were performed by professionals at the central hospital’s 
Cervical Pathology Clinic.
The variables studied included the following: the women’s 
age at the time of ASC-H identification, the number and type of 
cytological, colposcopic and histological results and the length 
of follow-up (months) among the women with ASC-H cytology, 
which ended with diagnostic confirmation, defined as diagnosis 
of a more severe lesion (CIN II+) or negative confirmation.
To define the cytological variable (Papanicolaou), the 2001 
Bethesda nomenclature was utilized. The results were classi-
fied as follows: negative for intraepithelial lesion or malignancy 
(Neg); atypical squamous cells of undetermined significance 
(ASCUS); atypical squamous cells that cannot exclude high-grade 
squamous intraepithelial lesion (ASC-H); low-grade squamous 
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intraepithelial lesion (LSIL); high-grade squamous intraepithelial 
lesion (HSIL); or squamous cell carcinoma. 
To define the histological variable (biopsy), cervical intraepi-
thelial neoplasia (CIN) grades were used and divided as follows: 
cervical intraepithelial neoplasia of low grade (CIN I); cervi-
cal intraepithelial neoplasia of moderate grade (CIN II); cervical 
intraepithelial neoplasia of high grade (CIN III); carcinoma in situ 
(CIS); or invasive carcinoma. 
For the colposcopic variable, a standard protocol was used, 
which included conventional visual examination, application of 
5% acetic acid and identification of the squamocolumnar junc-
tion. This variable was defined as follows: negative (-) colposcopy, 
when colposcopic findings did not show severe lesions or the 
need for a biopsy; or positive (+) colposcopy, when colposcopic 
findings showed lesions of severity that required biopsy.
The data collected were analyzed electronically using 
Microsoft Excel (version 2007) and the “Conditional Probabilities 
Tree Diagram,” which shows the number, type, outcome and time 
interval between patient tests. 
RESULTS
Out of the 88,438 cervical exfoliative smears collected, 752 
(0.85%) were atypical Pap smears. The latter contained atypical 
squamous cells, which were divided into atypical squamous cells 
of undetermined significance (ASC-US) (619 cytological tests, 
0.69%) and atypical squamous cells that cannot exclude high-
grade squamous intraepithelial lesion (ASC-H) (106 cytological 
tests, 0.11%) (Table 1).
After applying the selection criteria to the group of women 
with ASC-H Pap smears, the cohort consisted of 92 women, with 
a mean age of 38.2 years and an age range from 19 to 71 years.
The follow-up results from this cohort were illustrated using 
the “Conditional Probabilities Tree Diagram” (Figure 1), which 
begins with the ASC-H Pap smear (“phase 0”) and illustrates the 
tests performed on the women and their outcomes over time. 
Squares signify a biopsy and circles indicate a Pap smear. 
It needs to be borne in mind that the ASC-H cytological find-
ing is defined as a suspected case (positive Pap smear) in the cer-
vical cancer program. These 92 women who were attended at pri-
mary healthcare clinics were managed in accordance with the 
central hospital’s “management algorithm for specialist or cervical 
pathology clinic treatment from the time of the first atypical Pap”, 
in order to make the diagnosis and/or proceed with treatment. 
During the first contact with this clinic, the patient’s history 
was taken, a gynecological examination was made and colpos-
copy was performed. Colposcopy is considered to be the first 
procedure for diagnostic confirmation in the management algo-
rithm. As shown in “Phase 1”, 76 cases (82.6%) showed abnormal 
colposcopic findings and required biopsy for histological anal-
ysis, while in 16 cases (17.4%), the initial colposcopic findings 
were normal and were followed up by a Pap test. 
The average length of time taken for the patients to complete 
these medical procedures was 3.15 months, with a minimum of 
two days and a maximum of 19.6 months.
Subsequently, the cytological-histological results collected in 
the previous stage were known as “Phase 2”. For the group that 
started with a histological study, the results were distributed as 
follows: 31 biopsies showed CIN I; 35 showed CIN II/III; three 
showed carcinoma; and seven were negative. For the group that 
started with a Pap smear, three of these tests indicated HSIL, 11 
were negative for neoplastic cells and two indicated ASC-US. 
Given these results, and in accordance with the derivation algo-
rithm, a reassessment was performed and the previous proce-
dures were repeated. Pap and colposcopy were obligatory, while 
the histological examination was made according to the col-
poscopic findings.
In “Phase 3” and as a result of the repeated examinations, 12 
women were found (through biopsy) to have CIN I; 34 women 
were found to have CIN II/III; three women were found to have 
carcinoma and four women were negative. In the cases with Pap 
smears, 38 tests were performed and most of them (33) showed 
normal outcomes. These results mostly corresponded to patients 
Cytological finding Result Number %
Negative cytological findings
Satisfactory 77,411 87.53
Less than optimal 4,923 5.56
Inadequate 4,145 4.68
Atypical
Atypical squamous cells of undetermined significance (ASCUS) 619 0.69
Atypical squamous cells cannot exclude high-grade SIL (ASC-H) 106 0.11
Atypical glandular cells of undetermined significance (AGC-US) 25 0.02
Atypical glandular cells suggestive of adenocarcinoma in situ 2 0.00
Positive cytological findings 
Low-grade Pap 503 0.56
High-grade Pap 638 0.72
Invasive cancer 66 0.07
Total 88,438 99.94
Table 1. Exfoliative cervical cytological examinations from primary healthcare clinics in Santiago, Chile, 2005 - 2006
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who had been treated by means of surgical conization consequent 
to the diagnostic-treatment biopsies that were performed prior to 
gathering material for Pap smears. Following conization, and in 
accordance with the Chilean Ministry of Health’s guidelines, two 
Pap smears must be performed, with an interval of six months, 
before the patient returns to the primary healthcare clinic. 
In “Phase 4”, on the one hand, the outcomes from the earlier 
14 biopsies are shown: four were classified as carcinoma, six as 
high-risk lesions and four as low-risk lesions. On the other hand, 
cytological outcomes are shown, and these mostly related to 
patients according to the process of epidemiological monitoring. 
In “Phase 5,” there were also results with high-grade lesions 
from a total of 20 women. In “Phases 6 and 7”, the cases were pre-
dominantly monitored by means of Pap smears and there were 
four patients with CIN II/III and one with CIN I who was diag-
nosed via biopsy. 
In this diagnostic search process, 166 oncotic cytological tests 
were performed via conventional Pap smears, with an average of 
1.8 examinations per woman and a minimum of zero and maxi-
mum of five cytological tests per woman. With regard to histo-
logical examinations, the total numbers of uterine cervix biopsies 
guided by colposcopy was 158, with an average of 1.7 per woman, 
and a minimum of zero and maximum of four. The total number 
of cytological-histological examinations that patients required to 
obtain a definitive diagnosis was as follows: 
•	 1	biopsy	=	27	women	(29.3%);
•	 2	biopsies	=	46	women	(50%);
•	 3	biopsies	=	8	women	(8.7%);
•	 4	biopsies	=	3	women	(3.3%);
•	 2	Papanicolaou	smears	=	8	women	(8.7%);
The average length of time from the ASC-H Pap smear to 
the final diagnosis of the most severe lesion was 5.29 months 
in the biopsy group and 12.26 months in the Pap smear group. 
In evaluating this three-year cytological-histological follow-up 
period, the 92 women were found to have the following lesion 
distribution:
•	 7	women	had	invasive	carcinoma	(7.6%);
•	 49	women	had	high-grade	lesions	(53.3%);
•	 26	women	had	low-grade	lesions	(28.2%);
•	 10	women	had	normal	cytological	outcomes	(10.9%).
DISCUSSION
ASC-H is a type of atypical smear characterized by follow-up that 
includes a range of clinical procedures to reach a definitive diag-
nosis. Knowledge of the prevalence of women carrying ASC-H is 
essential for estimating the proportion of women at risk of devel-
oping a high-grade lesion. 
One of the first studies aimed at investigating the preva-
lence of this new cytological classification category was carried 
out by the College of American Pathologists in the United States 
in 2002-2003: this was a nationwide survey and it revealed that 
ASC-H represented approximately 0.2% of cytological interpre-
tations.12 These first studies indicated that using this category was 
relatively congruent with the frequency provided by the 2001 
Bethesda System.1 Thus, studies including this new category were 
started worldwide, thereby providing ranges of ASC-H preva-
lence. This prevalence ranged from 0.22% out of a total of 27,367 
Pap smears performed in a screening program in India, up 8.8% 
out of a total of 12,188 Pap smears in South Africa.13,14 
In Latin America, and specifically in Brazil, Yamamoto et al. 
found ASC-H smear prevalences of 0.23% in 2007 and 0.54% 
in 2008, out of a total of 56,179 smears collected through the 
Cervical Cancer Research and Control Program.15 Within this 
line of research, our study results, which demonstrated ASC-H 
prevalence of 0.11%, or 106 Pap smears out of a total of 88,438 
between 2005 and 2006, are congruent with the established 2001 
Bethesda System (Table 2).5,13-24 
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Figure 1. Follow-up of women with high-grade squamous intraepithelial lesions (ASC-H) in Chile.
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Concerning the percentage of ASC-H among the total 
volume of atypical squamous cells (ASC), the 2001 Bethesda 
System indicates that between 5 and 10% (approximately) 
should be expected.1,3 In our study, the ASC-H prevalence (106) 
represented 14% of the total atypia (752 women). The national 
survey conducted by the College of American Pathologists 
(2002-2003) found that 5% of the squamous atypias corre-
sponded to ASC-H.12 In Brazil, Yamamoto et al. obtained 2,622 
atypical Pap smears in 2007-2008 and 210 (0.8%) of these were 
ASC-H smears.15 
For the clinical management of patients with ASC-H smears, 
the American Society for Colposcopy and Cervical Pathology 
(ASCCP) published an algorithm in relation to clinical manage-
ment of these patients in order to unify the criteria.25 In Chile, and 
taking this algorithm into consideration, the Chilean Ministry of 
Health implemented its “Clinical Guidance for Cervical Cancer” 
(2005 and update 2010), which includes flow charts for clinical 
decision-making, such as the “management algorithm for spe-
cialists or Cervical Pathology Clinics (CPC) from the time of the 
first atypical Pap smear according to the 2001 Bethesda System” 
and the “algorithm of diagnostic confirmation”. In the first algo-
rithm, it is established that women with atypical smears must 
be managed at a cervical pathology clinic.26,27 The follow-up for 
our population study was started at a cervical pathology clinic. 
The population’s demographic profile comprised young women 
(average age: 38.2 years), which was similar to the populations 
of several other studies, which had averages ranging from 29 to 
38.1 years. It is noteworthy that these outcomes corresponded 
to women in the screened population (Table 3).6,13,17,18,28 
Reference Place and period Total Pap tests Number of  ASC-H cases Prevalence of ASC-H %
Louro et al.18 
Birmingham, USA
January 2000 to December 2001
43,840 368 0.84
Selvaggi19
Wisconsin, USA
March to September, 2002
9,214 25 0.27
Duncan and Jacob22 
Tennessee, USA
October 2002 to March 2004
60,390 414 0.69
Elsheikh et al.20 
Indiana, USA
July 2001 to July 2003
129,911 7,698 0.24
Barreth et al.17 
Alberta, Canada 
January to December 2002
241,841 727 0.30
Saad et al.16 
Pittsburgh, USA
January 2003 to June 2004
152,495 800 0.52
Gupta et al.13 
Noida, India
January 2001 to December 2004
27,367  60 0.22
Patton et al.5 
Tennessee, USA
March 2003 to December 2006
150,702 591 0.39
Okonda et al.14 
Swaziland, Southern Africa
June 2004 to May 2006
12,188 1,072 8.8
Alsharif et al.21 
Minnesota, USA
July 2004 to December 2007
235,645 1,219 0.52
Yamamoto et al.15 
São Paulo, Brazil
2007
30,869 72 0.23
Rekhi et al.23
Mumbai, Parel, India 
January 2005 to December 2008
9,190 29 0.31
Giorgi Rossi et al.24 
Italy
December 2007 to September 2008
3,410 10 0.29
Present study
Santiago, Chile
2005 to 2006
88,438 106 0.11
Table 2. Prevalence of atypical squamous cells that cannot exclude high-grade squamous intraepithelial lesions (ASC-H) in population 
screening studies
Reference Average age
Louro et al.18 36.8
Barreth et al.17 29.0
Gupta et al.13 38.1
Bonvicino et al.6 35.6
McHale et al.28 32.8
Present study 38.2
Table 3. Average age of women with atypical squamous cells that 
cannot exclude high-grade squamous intraepithelial lesions (ASC-H) in 
population screening studies
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Reference
Women with ASC-H with histological 
follow-up
Women with CIN II or higher
Selvaggi19 22 15 women (68%) 
Louro et al.18 
Pap test preparation types with ASC-H:
190 conventional smear
28 liquid-based preparation (ThinPrep)
Prevalence of CIN II+ according to Pap test preparation type:
Liquid-based preparations = 9 (45%)
Conventional smears = 70 (46.1%)
There was no statistically significant difference in the incidence of CIN II or higher on 
subsequent biopsies after interpretation of ASC-H based on the preparation type
Duncan and Jacob22 99 40 women (40.4%)
Barreth et al.17 
Follow-up on 517 women:
Histological = 454 
Cytological alone = 63
Prevalence of CIN II+ or HSIL according to examination type:
Histological = 363 (79.9%)
Cytological alone = 11 (17.5%)
Saad et al.16 
Cytological and histological follow-up on 
women:
127 perimenopausal
90 postmenopausal
Prevalence of CIN II+ or HSIL according to menopausal period:
perimenopausal = 28 (22.0%) 
postmenopausal = 5 (6%)
Elsheikh et al.20 
Comparative:
Women with ASCUS = 410
Women with ASC-H = 110
Prevalence of CIN II+ according to epithelial cell abnormalities:
ASCUS = 35 women (8.5%) 
ASC-H = 49 women (44.6%)
Srodon et al.3 
Histological follow-up on HPV (+) 
women
ASCUS = 266
ASC-H = 45
Prevalence of CIN II+ in HPV(+) patients:
ASCUS = 27 (10.2%)
ASC-H = 18 (40.0%)
McHale et al.28 Histological follow-up on 229 women 
Prevalence of CIN II/III according to time:
At the initial colposcopy, 23 of the patients (10%) had histological evidence of CIN 
II/III. 
The cumulative risk of CIN II/III was 12.2% at 12 months
Gupta et al.13 
Colposcopic-histological follow-up:
ASCUS = 218 women
ASC-H = 52
Prevalence of CIN II/III or higher according to epithelial cell abnormalities:
ASCUS = 7 (3.2%)
ASC-H = 16 (30.8%) 
Bonvicino et al.6 Histological follow-up on 122 women
Number of follow-up cervical biopsies for  a definitive diagnosis of CIN II+ 
First = 35 (72%)
Second = 7 (14%)
Third = 4 (8%)
Fourth = 3 (6%)
Total: 49 women (40%) with CIN II+
Mokhtar et al.29 Histological follow-up on 123 women
Prevalence ratio of CIN II/III according to age group 
> 40 years = 65.1%
< 40 years = 47.5%
Patton et al.5 
Histological follow-up on 195 women
Postmenopausal  = 89 women
Pregnant = 44 women
Postpartum= 27 women
Contraceptive use = 35 women
Prevalence of CIN II+:
Postmenopausal: 20 women (22.5%)
Pregnant: 35 women (79.6%)
Postpartum 18 women (66.7%)
Contraceptive use: 21 (60%)
The diagnosis of ASC-H in postmenopausal Pap smears has a low predictive value in 
stark contrast to the pregnant, postpartum, and contraceptive-use categories
Alsharif et al.21 Histological follow-up on 691 women
Prevalence of CIN II+ according to cytologic categories:
LSIL = 370 (16.1%)
LSIL-H = 112 (33.1%)
HSIL = 468 (69.0%)
ASC-H = 182 (26.3%)
Cytryn et al.7 Histological follow-up on 57 women
Prevalence of CIN II/III according to age group of women :
< 50 years = 10 (22.2%)
50 years or older = 1 (8.3%)
Total: 11 women (19.3%) biopsy with CIN II+
Present study 92
Prevalence of CIN II+:
56 women (60.9%)
Table 4. Outcomes from histology follow-up of women with smears showing atypical squamous cells that cannot exclude high-grade 
squamous intraepithelial lesions (ASC-H)
CIN = cervical intraepithelial neoplasia; LSIL = low grade squamous intraepithelial lesion; HSIL = high grade squamous intrapithelial lesion.
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In the present study, women with ASC-H atypia underwent 
on average 1.8 cytological tests per woman (0 to 5 Pap smears) 
and half of them (46 women) underwent a minimum of two 
biopsies, in order to reach the definite CIN II+ diagnosis. It is 
possible to compare these outcomes with Bonvicino’s data, in 
which among 260 ASC-H smears, there was an average cytologi-
cal-histological follow-up of 1.35 Pap smears per woman, with a 
range of 1 to 4, and the biopsy follow-up consisted of an average 
of 0.64 biopsies per woman. In other words, the majority of the 
women (72%) underwent only one biopsy for a diagnosis of CIN 
II+ to be reached.6
The average length of follow-up in the present study was 
5.29 months, to reach the most severe diagnosis (CIN II+), using 
only the biopsy. For confirmation of this cytological-histolog-
ical diagnosis, a period of 12.26 months was needed, during 
which two normal cytological examinations were needed, with 
an interval of six months between them. These results are con-
trary to those of Bonvicino, in which the CIN II/III diagnosis 
required 18.5 months.6
In our study, 60.9% (56 women) had a definitive high-grade 
diagnosis (CIN II+) that was verified by biopsy. Comparing 
this ratio with the literature, we found that it was interme-
diate between the studies by Saad et al.16 and Barreth et al.,17 
which found that 6% and 79.9% of the women had high-grade 
lesions, respectively. Table 4 shows 14 studies in which differ-
ent variables were analyzed. For instance, Louro et al.18 made a 
comparison between conventional collection and liquid-based 
smears, and found that in spite of being different techniques 
for cytological sample collection, they resulted in similar defin-
itive diagnoses of CIN II.18 This is consistent with the results 
obtained from the majority of the studies observed, which dem-
onstrated CIN II+ prevalences of more than 40%, according to 
the biopsy results.3,5,6,17-24,29
Our results confirmed that at the time of the first ASC-H 
report, immediate intervention with colposcopy was necessary, 
followed by a biopsy. This validates the medical management of 
ASC-H that is required by the “management algorithm from the 
time of the first atypical Pap,” which is included in the Chilean 
Ministry of Health’s Clinical Guidelines for Cervical Cancer.
CONCLUSIONS
The follow-up of our cohort of women showed the following: 
•	 The	majority	of	the	uncertain	ASC-H	diagnoses	(82.6%)	also	
had abnormal colposcopic results.  
•	 During	 the	 follow-up	 on	ASC-H	 smears,	 two	 out	 of	 every	
three women developed high-grade lesions (CIN II+), which 
were detected after an average of 3.15 months.
•	 Detection	 of	 high-grade	 lesions	 in	 a	 female	 population	
through screening reflects the importance of public health 
programs within the National Cervical Cancer Research and 
Control Program in Chile.
REFERENCES
1. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: 
terminology for reporting results of cervical cytology. JAMA. 
2002;287(16):2114-9.
2. Sherman ME, Solomon D, Schiffman M, ASCUS LSIL Triage Study 
Group. Qualification of ASCUS. A comparison of equivocal LSIL and 
equivocal HSIL cervical cytology in the ASCUS/LSIL Triage Study. Am 
J Clin Pathol. 2001;116(3):386-94.
3. Srodon M, Parry Dilworth H, Ronnett BM. Atypical squamous 
cells, cannot exclude high-grade squamous intraepithelial lesion: 
diagnostic performance, human papillomavirus testing, and follow-
up results. Cancer. 2006;108(1):32-8.
4. Sherman ME, Castle PE, Solomon D. Cervical cytology of atypical 
squamous cells-cannot exclude high-grade squamous intraepithelial 
lesion (ASC-H): characteristics and histologic outcomes. Cancer. 
2006;108(5):298-305.
5. Patton AL, Duncan L, Bloom L, Phaneuf G, Zafar N. Atypical squamous 
cells, cannot exclude a high-grade intraepithelial lesion and its 
clinical significance in postmenopausal, pregnant, postpartum, and 
contraceptive-use patients. Cancer. 2008;114(6):481-8.
6. Bonvicino A, Huitron S, Fadare O. Papanicolaou test interpretations 
of “atypical squamous cells, cannot exclude high-grade squamous 
intraepithelial lesion’’: an investigation of requisite duration and 
number of colposcopic procedures to a definitive diagnosis of high-
grade dysplasia in routine practice. Cancer. 2007;111(6):477-81.
7. Cytryn A, Russomano FB, Camargo MJ, et al. Prevalence of cervical 
intraepithelial neoplasia grades II/III and cervical cancer in patients 
with cytological diagnosis of atypical squamous cells when high-
grade intraepithelial lesions (ASC-H) cannot be ruled out. Sao Paulo 
Med J. 2009;127(5):283-7.
8. Gobierno de Chile. Ministerio de Salud. División Prevención Y 
Control de Enfermedades. Depto Enfermedades no Transmisibles. 
Terminología para el informe citológico de muestras cervicales (PAP). 
Available from: http://www.redsalud.gov.cl/archivos/cancer/Informa_
cambio_Nomenclatura_2005.pdf. Accessed in 2013 (Apr 16).
9. Base de datos Cito-Expert: Consolidado nacional citologías e 
histologías [Acceso en línea, restringido a servicios de salud 
pertenecientes a la red pública de atención del Minsal, Chile]. Chile: 
Laboratorio Nacional de Referencia. Ministerio de Salud Chile. 
10. Gaete JL, Fuhrer K, Soto R, Rojas JL. Pap atípico escamoso: ¿un falso 
negativo? [Squamous atypical vaginal smears: a false negative?] Clin 
Cienc. 2003;1(6):13-24.
11. Yazigi I R, Rodríguez A T, Contreras M L, Alcaíno M MI. El significado 
clínico de dos papanicolaou atípicos consecutivos [Clinical 
significance of 2 consecutive atypical Pap smears]. Rev Chil Obstet 
Ginecol. 2005;70(6):386-90.
ORIGINAL ARTICLE | López-Alegría F, De Lorenzi DS, Quezada OP
22     Sao Paulo Med J. 2014; 132(1):15-22
12. Davey DD, Neal MH, Wilbur DC, et al. Bethesda 2001 implementation 
and reporting rates: 2003 practices of participants in the College 
of American Pathologists Interlaboratory Comparison Program in 
Cervicovaginal Cytology. Arch Pathol Lab Med. 2004;128(11):1224-9.
13. Gupta S, Sodhani P, Chachra KL, Singh V, Sehgal A. Outcome of 
‘‘Atypical squamous cells’’ in a cervical cytology screening program: 
implications for follow up in resource limited settings. Diagn 
Cytopathol. 2007;35(11):677-80.
14. Okonda S, Wright C, Michelow P. The status of cervical cytology 
in Swaziland, Southern Africa: a descriptive study. Cytojournal. 
2009;6:14.
15. Yamamoto LSU, Pereira SMM, Etlinger D, et al. Frequência de 
diagnóstico de lesões do colo uterino por faixa etária em mulheres 
atendidas no Programa de Rastreamento Viva Mulher no período 
de 2004 a 2008 [Review on the occurrence of uterine cervix lesions 
according to age group among women enrolled in the Viva Mulher – 
Prevention Program during the period from 2004 to 2008]. Rev Inst 
Adolfo Lutz. 2009;68(1):126-32.
16. Saad RS, Dabbs DJ, Kordunsky L, et al. Clinical significance of cytologic 
diagnosis of atypical squamous cells, cannot exclude high grade, in 
perimenopausal and postmenopausal women. Am J Clin Pathol. 
2006;126(3):381-8.
17. Barreth D, Schepansky A, Capstick V, et al. Atypical squamous cells-
cannot exclude high-grade squamous intraepithelial lesion (ASC-H): 
a result not to be ignored. J Obstet Gynaecol Can. 2006;28(12):1095-8.
18. Louro AP, Roberson J, Eltoum I, Chhieng DC. Atypical squamous cells, 
cannot exclude high-grade squamous intraepithelial lesion. A follow-
up study of conventional and liquid-based preparations in a high-risk 
population. Am J Clin Pathol. 2003;120(3):392-7.
19. Selvaggi SM. Reporting of atypical squamous cells, cannot exclude 
a high-grade squamous intraepithelial lesion (ASC-H) on cervical 
samples: is it significant? Diagn Cytopathol. 2003;29(1):38-41.
20. Elsheikh TM, Kirkpatrick JL, Wu HH. The significance of ‘‘low-grade 
squamous intraepithelial lesion, cannot exclude high-grade 
squamous intraepithelial lesion’’ as a distinct squamous abnormality 
category in Papanicolaou tests. Cancer. 2006;108(5):277-81.
21. Alsharif M, Kjeldahl K, Curran C, et al. Clinical significance of the 
diagnosis of low-grade squamous intraepithelial lesion, cannot 
exclude high-grade squamous intraepithelial lesion. Cancer. 
2009;117(2):92-100.
22. Duncan LD, Jacob SV. Atypical squamous cells, cannot exclude a 
high-grade squamous intraepithelial lesion: the practice experience 
of a hospital-based reference laboratory with this new Bethesda 
system diagnostic category. Diagn Cytopathol. 2005;32(4):243-6.
23. Rekhi B, Ajit D, Joseph SK, Gawas S, Deodhar KK. Evaluation of atypical 
squamous cells on conventional cytology smears: An experience 
from a screening program practiced in limited resource setting. 
Cytojournal. 2010;7:15.
24. Giorgi Rossi P, Chini F, Bisanzi S, et al. Distribution of high and low risk 
HPV types by cytological status: a population based study from Italy. 
Infect Agent Cancer. 2011;(6):2.
25. Wright TC Jr, Cox JT, Massad LS, et al. 2001 Consensus Guidelines for 
the management of women with cervical cytological abnormalities. 
JAMA. 2002;287(16):2120-9.
26. Ministerio de Salud. Guía clínica cancer cervicouterino 2. 1st ed. 
Santiago: Minsal; 2005. Available from: http://www.redsalud.gov.
cl/archivos/guiasges/CancerCervicouterino.pdf. Accessed in 2013 
(Mar 15).
27. Ministerio de Salud. Guía clínica cancer cervicouterino. Revisión y 
Actualización Santiago: Minsal; 2010. Available from: http://www.
redsalud.gov.cl/portal/url/item/720bfefe91e9d2ede04001011f010
ff2.pdf. Accessed in 2013 (Mar 15).
28. McHale MT, Souther J, Elkas JC, Monk BJ, Harrison TA. Is atypical 
squamous cells that cannot exclude high-grade squamous 
intraepithelial lesion clinically significant? J Low Genit Tract Dis. 
2007;11(2):86-9.
29. Mokhtar GA, Delatour NL, Assiri AH, et al. Atypical squamous 
cells, cannot exclude high-grade squamous intraepithelial lesion: 
cytohistologic correlation study with diagnostic pitfalls. Acta Cytol. 
2008;52(2):169-77.
Acknowledgements: Barbara Rivera Lopez was responsible for style 
correction of the manuscript
Sources of funding: None 
Conflict of interest: None
Date of first submission: September 12, 2012 
Last received: December 21, 2012 
Accepted: April 24, 2013 
Address for correspondence:  
Fanny López Alegría  
Capullo, 2245  
Providencia — Santiago — Chile 
CEP 7510-196 
Tel. (56-2) 84729215 
E-mail: fanny.lopez@usach.cl
